Form 4: Galectin Therapeutics CMO Sells Shares

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, exercised stock options and immediately sold 8,125 shares of common stock for a weighted average price of $4.0725 per share.

Summary

• Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc. (GALT), reported a transaction on December 31, 2025.
• The transaction involved the exercise of 8,125 stock options at an exercise price of $1.23 per share.
• Concurrently, 8,125 shares of common stock were sold at a weighted average price of $4.0725 per share.
• The sale price ranged from $4.00 to $4.15 per share.
• Both transactions were executed under a Rule 10b5-1 plan adopted by Mr. Jamil on July 15, 2025.
• Following these transactions, Mr. Jamil beneficially owns 0 direct common shares and 40,625 derivative securities (stock options).
• Remaining options vest as follows: 16,250 on June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.
• The stock options have an expiration date of January 23, 2035.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale via a Rule 10b5-1 plan, which is a routine event. While it's a sale, the pre-planned nature and relatively small size for a public company mitigate any strong negative sentiment. The insider profited from the transaction.

Positives

• The Chief Medical Officer realized a profit from exercising stock options and selling the shares, indicating personal financial benefit.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which demonstrates a structured approach to insider trading and can mitigate concerns about opportunistic selling.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the amount is relatively small.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction and does not provide information that allows for an analysis of broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of 8,125 shares by a Chief Medical Officer is a minor dilution event and a routine insider transaction, unlikely to have a significant impact on the broader shareholder base. The pre-planned nature through a 10b5-1 plan reduces concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Future vesting of 16,250 stock options on June 30, 2026.
• Future vesting of 16,250 stock options on December 31, 2026.

Key Dates

Keywords

GALT, Galectin Therapeutics, Khurram Jamil, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1 Plan, Chief Medical Officer